Harm reduction and morally controversial behaviours: New legal and policy approaches to drug use, sex work, and physician-assisted dying
23 March 2015, 12h-14h, NCDH 316
Le Groupe de recherche en sant茅 et droit de 不良研究所 vous conviait 脿 sa derni猫re conf茅rence de l'ann茅e universitaire, laquelle fut pr茅sent茅e par deux de ses membres, la professeure Alana Klein et le professeur Daniel Weinstock.
The speakers considered the growing tendency among public actors to reframe what were once considered morally controversial questions in terms of the reduction of harm.
Drawing on the examples of contemporary debates and legal developments around drug use sex work, and physician assisted dying, the workshop considered the potential benefits, risks and consequences of engaging with controversial issues through the logic and lens of harm reduction.
For example, it explored what motivates this type of framing, whether it can help achieve overlapping consensus around these fractious issues, as well as the moral limits of the use of this kind of reasoning in political and legal deliberation.
Population Biobanking, Autonomy and the Duty to Inform: Streamlining Access to Data while Protecting Participants
2 February聽2015, 12h30-14h00, NCDH 316
Ma鈥檔 H. Zawati, Academic Coordinator at the 不良研究所 Centre of Genomics and Policy and DCL candidate at the Faculty of Law, gave a Seminar on Health and Law.
Abstract
In research, Canadian courts have maintained that participants are entitled to a "full and frank disclosure" and that researchers' duties in that regard are as great, if not greater, than the duties owed by physicians in the clinical setting. That being said, the increasingly longitudinal and international nature of research challenges the feasibility of maintaining such an expansive duty to inform.
Take population biobanks as an example. These longitudinal studies are limited in terms of what information they can provide to research participants during the initial consent process.
On the one hand, they are increasingly encouraged to provide access to their collections, but on the other hand, they are unable to provide participants with 鈥渇ull disclosure鈥� on the future use of their data at the time of recruitment.
By re-examining conceptions at the heart of the legal duty to inform, this presentation will discuss ways in which population biobanks can continue to streamline access to data while protecting research participants.
Speaker
Ma鈥檔 H. Zawati (LLB, LLM) is a lawyer and the Academic Coordinator of the Centre of Genomics and Policy at 不良研究所. He is currently completing his Doctoral degree in law (DCL) at 不良研究所 and is the Graduate Member of the 不良研究所 Research Group on Health and Law. Me Zawati is also an Associate Member of the University鈥檚 Biomedical Ethics Unit since 2013. His research focuses on the legal and ethical aspects of biobanking as well as the legal duties and liability of health care professionals in both the clinical and research settings. He has published numerous articles on issues such as access to genomic databases, the return of research results/incidental findings, the legal liability of physicians and the closure of biobanks. Me Zawati has also presented on these topics in Canada and internationally. Recently, the Young Bar Association of Montreal has named him as one of its 鈥淟awyer of the Year鈥� awardees for 2014.
Quelques d茅fis de l鈥檌nt茅gration des m茅decines non conventionnelles dans un syst猫me de soins cart茅sien
27 novembre 2014, 12h00-13h30, salle 316, Nouveau Pavillon Chancellor-Day
Conf茅rence du Groupe de recherche en Sant茅 et Droit avec le professeur Olivier Guillod, Directeur de l鈥橧nstitut de droit de la sant茅, Universit茅聽de Neuch芒tel, Suisse.
搁茅蝉耻尘茅
Dans les pays occidentaux, la population demande, et utilise, de plus en plus de diverses m茅decines dites non-conventionnelles. Les uns y voient une ouverture bienvenue vers d鈥檃utres approches 脿 la sant茅 humaine. Les autres craignent un retour de l鈥檕bscurantisme.
Les juristes sont interpel茅s : quelle place am茅nager dans l鈥檕rdre juridique pour les m茅decines non-conventionnelles ? Faut-il r猫glementer leur pratique ? Faut-il les rembourser par la s茅curit茅 sociale ?
Ces questions, et d鈥檃utres, seront explor茅es 脿 partir de l鈥檈xemple de la Suisse, seul pays europ茅en 脿 avoir un article de sa Constitution consacr茅 脿 ces m茅decines.
